Should I buy or sell Merus stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks .

What is Merus' stock price target for 2024?

10 analysts have issued 1-year target prices for Merus' shares. Their MRUS share price targets range from $45.00 to $69.00. On average, they expect the company's share price to reach $56.33 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts .

How have MRUS shares performed in 2024?

Merus' stock was trading at $27.50 on January 1st, 2024. Since then, MRUS shares have increased by 49.3% and is now trading at $41.05. View the best growth stocks for 2024 here .

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MRUS earnings forecast .

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.38. The biotechnology company earned $8.94 million during the quarter, compared to analyst estimates of $10.43 million. Merus had a negative trailing twelve-month return on equity of 50.61% and a negative net margin of 352.56%.

What ETFs hold Merus' stock?

ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Range Cancer Therapeutics ETF (CNCR) . BlackRock Future Health ETF (BMED) .

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE) , Micron Technology (MU) , OPKO Health (OPK) , Corbus Pharmaceuticals (CRBP) , Exelixis (EXEL) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC) .

Merus (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Medicxi Ventures Management Jersey Ltd (1.99%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De , Lex Bakker , Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends .

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:MRUS

Merus (MRUS) Stock Price, News & Analysis

→ The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad)

Free MRUS Stock Alerts

$40.78

-0.27 (-0.66%)

(As of 10:46 AM ET)

Compare

Today's Range: $40.60
▼
$41.38
50-Day Range: $40.06
▼
$51.82
52-Week Range: $18.21
▼
$52.03

Volume: 22,230 shs
Average Volume: 565,582 shs
Market Capitalization: $2.39 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $56.33

Get Merus alerts:

Merus MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 37.2% Upside
$56.33 Price Target
Short Interest: Healthy
5.86% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.49
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.29) to ($3.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.69 out of 5 stars

Medical Sector

418th out of 913 stocks

Pharmaceutical Preparations Industry

190th out of 427 stocks

4.5

Analyst's Opinion

Consensus Rating
Merus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Merus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
5.86% of the outstanding shares of Merus have been sold short.
Short Interest Ratio / Days to Cover
Merus has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Merus has recently decreased by 16.10%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Merus does not currently pay a dividend.
Dividend Growth
Merus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MRUS.

1.9

News and Social Media Coverage

News Sentiment
Merus has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Merus this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merus insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Merus is held by insiders.
Percentage Held by Institutions
96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Merus are expected to decrease in the coming year, from ($3.29) to ($3.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merus is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merus is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Merus has a P/B Ratio of 6.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About Merus Stock (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRUS Stock News Headlines

April 13, 2024 | americanbankingnews.com

Merus (NASDAQ:MRUS) Stock Rating Reaffirmed by Needham & Company LLC

April 10, 2024 | investing.com

Merus reports progress on cancer therapy at AACR meeting

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 8, 2024 | finanznachrichten.de

Merus N.V.: Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

April 8, 2024 | globenewswire.com

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

April 3, 2024 | finance.yahoo.com

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

March 11, 2024 | finance.yahoo.com

MRUS Dec 2024 50.000 call

March 10, 2024 | finance.yahoo.com

MRUS Jan 2025 50.000 put

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

March 9, 2024 | finance.yahoo.com

MRUS Apr 2024 35.000 put

March 9, 2024 | finance.yahoo.com

MRUS Apr 2024 40.000 call

March 6, 2024 | marketwatch.com

Gilead, Merus to Collaborate on Trispecific Antibody Research

March 6, 2024 | msn.com

Gilead to invest in Merus as part of a research deal

March 6, 2024 | finance.yahoo.com

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

March 6, 2024 | finance.yahoo.com

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

March 5, 2024 | finance.yahoo.com

Merus Full Year 2023 Earnings: Misses Expectations

March 4, 2024 | markets.businessinsider.com

Strong Buy Rating for Merus’s Peto: Anticipating High Market Potential and Synergistic Treatment Efficacy

March 2, 2024 | finance.yahoo.com

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported And Analysts Are Trimming Their Forecasts

March 1, 2024 | seekingalpha.com

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

March 1, 2024 | markets.businessinsider.com

Merus’s Upgraded Outlook: Buy Rating and Price Target Boost Amid Promising Drug Trials and Financial Stability

February 29, 2024 | finance.yahoo.com

MRUS Apr 2024 40.000 put

February 29, 2024 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Merus (MRUS)

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Merus’s Stock Amid Strong Clinical Developments and Market Potential

February 28, 2024 | finanznachrichten.de

Merus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

February 28, 2024 | globenewswire.com

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

February 16, 2024 | finance.yahoo.com

MRUS Mar 2024 40.000 call

February 16, 2024 | finance.yahoo.com

MRUS Sep 2024 55.000 call

See More Headlines

Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MRUS
CUSIP: N/A
CIK: 1651311
Web: www.merus.nl
Phone: (130) 253-8800
Fax: N/A
Employees: 172
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $56.33
High Stock Price Target: $69.00
Low Stock Price Target: $45.00
Potential Upside/Downside: +37.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-154,940,000.00
Net Margins: -352.56%
Pretax Margin: -345.30%
Return on Equity: -50.61%
Return on Assets: -37.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.34
Quick Ratio: 5.34

Sales & Book Value

Annual Sales: $43.95 million
Price / Sales: 54.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.17 per share
Price / Book: 6.65

Miscellaneous

Outstanding Shares: 58,690,000
Free Float: 56,164,000
Market Cap: $2.41 billion
Optionable: Optionable
Beta: 1.10

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Sven Ante Lundberg M.D. (Age 61)
CEO, President & Executive Director
Comp: $953.06k
Mr. Gregory D. Perry (Age 64)
Chief Financial Officer
Comp: $63.76k
Mr. Peter B. Silverman J.D. (Age 46)
EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Comp: $601.19k
Dr. Hui Liu Ph.D. (Age 57)
Chief Business Officer, Executive VP & Head of Merus U.S.
Comp: $597.7k
Dr. Andrew Joe M.D. (Age 57)
Chief Medical Officer & Senior VP
Comp: $692.74k
Dr. Hennie Hoogenboom
Co-Founder and Scientific Advisor
Harry Shuman
Chief Accounting Officer
Mr. Cornelis Adriaan de Kruif Ph.D. (Age 59)
CTO & Executive VP
Comp: $350.85k
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Senior VP
Kathleen Farren
IR & Corporate Communications Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Merus stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings or view top-rated stocks.
What is Merus' stock price target for 2024?: 10 analysts have issued 1-year target prices for Merus' shares. Their MRUS share price targets range from $45.00 to $69.00. On average, they expect the company's share price to reach $56.33 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price.
View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts.
How have MRUS shares performed in 2024?: Merus' stock was trading at $27.50 on January 1st, 2024. Since then, MRUS shares have increased by 49.3% and is now trading at $41.05.
View the best growth stocks for 2024 here.
When is Merus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRUS earnings forecast.
How were Merus' earnings last quarter?: Merus (NASDAQ:MRUS) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.38. The biotechnology company earned $8.94 million during the quarter, compared to analyst estimates of $10.43 million. Merus had a negative trailing twelve-month return on equity of 50.61% and a negative net margin of 352.56%.
What ETFs hold Merus' stock?: ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Range Cancer Therapeutics ETF (CNCR).BlackRock Future Health ETF (BMED).

What other stocks do shareholders of Merus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC).
When did Merus IPO?: Merus (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?: Merus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Medicxi Ventures Management Jersey Ltd (1.99%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg.
View institutional ownership trends.
How do I buy shares of Merus?: Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRUS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial